Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed later-stage tilt small index

Hyperlipidemia, Familial Combined: later-stage trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Hyperlipidemia, Familial Combined: 1 US clinical trial tracked, none currently recruiting.

Hyperlipidemia, Familial Combined is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Daiichi Sankyo, running 1 of these trials.

Enrollment posture brief

Registry condition hyperlipidemia-familial-combined

OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Hyperlipidemia, Familial (th…0%
Open-enrollment share among volume-matched conditions near Hyperlipidemia, Familial Combined

Hyperlipidemia, Familial Combined has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hyperlipidemia, Familial Combined on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hyperlipidemia, Familial Combined is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 41

Phase Distribution

PhaseTrial count
Phase 4 1

Top Sponsors

Daiichi Sankyo 1 trials

Named interventions

Most-linked intervention names on Hyperlipidemia, Familial Combined records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

fenofibrate tablets and Welchol placebo tablets Drug
1 trials
colesevelam HCl tablets and fenofibrate tablets Drug
1 trials

US sites by state

Facility locations filed on Hyperlipidemia, Familial Combined trials. A trial with sites in several states counts in each.

Virginia 1 trials
Texas 1 trials
Ohio 1 trials
North Carolina 1 trials
Kansas 1 trials
Illinois 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hyperlipidemia, Familial Combined page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Hyperlipidemia, Familial Combined trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Daiichi Sankyo sponsors the most Hyperlipidemia, Familial Combined trials on record, review their full trial history before evaluating a specific study. See Daiichi Sankyo's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hyperlipidemia, Familial Combined condition card totals 1 registered trials; most-linked intervention fenofibrate tablets and Welchol placebo tablets; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.